PuSH - Publication Server of Helmholtz Zentrum München

Rottenkolber, M.* ; Rottenkolber, D. ; Fischer, R.* ; Ibáñez, L.* ; Fortuny, J.* ; Ballarin, E.* ; Sabaté, M.* ; Ferrer, P.* ; Thürmann, P.* ; Hasford, J.* ; Schmiedl, S.*

Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients.

Respir. Med. 108, 1075-1090 (2014)
Open Access Green as soon as Postprint is submitted to ZB.
OBJECTIVE: Empirical results indicate an increased risk for cardiovascular (CV) adverse drug events (ADE) in chronic obstructive pulmonary disease (COPD) patients treated with beta-2-agonists (B2A) and muscarinic antagonists (MA). A systematic review (including a meta-analysis for drug classes with sufficient sample size) was conducted assessing the association between B2A or MA and acute myocardial infarctions (MI) in COPD patients. METHODS: Comprehensive literature search in electronic databases (MEDLINE, Cochrane database) was performed (January 1, 1946-April 1, 2013). Results were presented by narrative synthesis including a comprehensive quality assessment. In the meta-analysis, a random effects model was used for estimating relative risk estimates for acute MI. RESULTS: Eight studies (two systematic reviews, two randomized controlled trials, and four observational studies) were comprised. Most studies comparing tiotropium vs. placebo showed a decreased MI risk for tiotropium, whereas for studies with active control arms no clear tendency was revealed. For short-acting B2A, an increased MI risk was shown after first treatment initiation. For all studies, a good quality was found despite some shortcomings in ADE-specific criteria. A meta-analysis could be conducted for tiotropium vs. placebo only, showing a relative risk reduction of MI (0.74 [0.61-0.90]) with no evidence of statistical heterogeneity among the included trials (I(2) = 0%; p = 0.8090). CONCLUSIONS: An MI-protective effect of tiotropium compared to placebo was found, which might be attributable to an effective COPD treatment leading to a decrease in COPD-related cardiovascular events. Further studies with effective control arms and minimal CV risk are required determining precisely tiotropium's cardiovascular risk.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Acute Myocardial Infarction ; Beta-2-agonists ; Chronic Obstructive Pulmonary Disease ; Muscarinic Antagonists ; Systematic Review
ISSN (print) / ISBN 0954-6111
e-ISSN 1532-3064
Quellenangaben Volume: 108, Issue: 8, Pages: 1075-1090 Article Number: , Supplement: ,
Publisher Elsevier
Reviewing status Peer reviewed
Institute(s) Institute of Health Economics and Health Care Management (IGM)
German Center for Lung Research (DZL)